echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Infection > Treatment of drug-resistant tuberculosis with gamma delta T cells with a cure rate of up to 87.5%

    Treatment of drug-resistant tuberculosis with gamma delta T cells with a cure rate of up to 87.5%

    • Last Update: 2022-11-14
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit

    On December 15, 2021, Shenzhen Third People's Hospital/National Clinical Research Center for Infectious Diseases, Jinan University, Guangdong Tuberculosis Control Center and other research teams carried out the world's first clinical study on γδ T cells in the treatment of drug-resistant tuberculosis, after three years, the research result "Allogeneic Vγ9Vδ2 T-Cell Therapy Promotes Pulmonary Lesion Repair: An.
    " Open-labeled, Single-arm, Pilot Study in Patients with Multidrug-Resistant Tuberculosis" was published in the journal Frontiers in Immunology (latest impact factor 7.

    The study is the first in the world to use in vitro amplified allogeneic Vγ9Vδ2 T cells for the treatment of patients with
    multidrug-resistant TB.
    A total of 8 patients with MDR-TB were enrolled, seven of whom received both allogeneic Vγ9Vδ2 T cell therapy and anti-tuberculosis drug therapy
    Each patient was given 1 infusion of Vγ9Vδ2 T cells every 2 weeks, with 1×108 cells infused for a total of 12 courses and followed up for 6 months (Figure 1).

    The eighth patient initially received only 4 courses of cell infusion, followed by 8 courses of cell therapy and anti-tuberculosis drugs, followed for 6 months
    The safety and efficacy
    of cell therapy were evaluated from the aspects of clinical response, blood routine, biochemical indexes, chest CT images, immune cell surface markers, body weight and mycobacterium sputum detection.
    A total of 96 cell transfusions were performed in 8 patients without any adverse reactions, indicating that allogeneic Vγ9Vδ2 T cell therapy has a good safety profile
    At the same time, the results of chest CT showed that the lung lesions of all patients were significantly reduced, and the immune function assessment showed that the patient's immune function was also partially improved, and 7 patients had tested negative for tuberculosis for 3 consecutive times before the end of the course of treatment, and the cure rate was as high as 87.

    This single-arm, single-center clinical preliminary study opens a new avenue for drug-resistant TB treatment, demonstrating that allogeneic Vγ9Vδ2 T cells can be used as novel drugs for tuberculosis immunotherapy, providing a new option
    for the treatment of drug-resistant tuberculosis worldwide.

    Figure 1.
    Clinical design workflow for gamma delta T cells for drug-resistant tuberculosis

    The research work was supported
    by the National Key Research and Development Program of China, the National Natural Science Foundation of China, the Science and Technology Plan of Guangdong Province, and the Science and Technology Plan of Shenzhen Municipality.

    The paper link is:


    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.